Involvement of free radicals and oxidative stress in NAFLD/NASH

References

• Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 2012;23:345–352.
   Google Scholar
• Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008;60:311–357.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009;87:679–695.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med 2006;12:555–558.
   PubMed Web of Science ®Google Scholar
• Puri P, Wiest MM, Cheung O, Mirshahi F, Sargeant C, Min HK, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009;50:1827–1838.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non- alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55: 2005–2023.
   PubMed Web of Science ®Google Scholar
• Gawrieh S, Opara EC, Koch TR. Oxidative stress in nonalcoholic fatty liver disease: pathogenesis and antioxidant therapies. J Investig Med 2004;52:506–514.
   PubMed Web of Science ®Google Scholar
• Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quiñones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004;106:261–268.
   PubMed Web of Science ®Google Scholar
• Erhardt A, Stahl W, Sies H, Lirussi F, Donner A, Häussinger D. Plasma levels of vitamin E and carotenoids are decreased in patients with Nonalcoholic Steatohepatitis (NASH). Eur J Med Res 2011;16:76–78.
   PubMed Web of Science ®Google Scholar
• Liu S, Shi W, Li G, Jin B, Chen Y, Hu H, et al. Plasma reactive carbonyl species levels and risk of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26: 1010–1015.
   PubMed Web of Science ®Google Scholar
• Pratico D, Iuliano L, Basili S, Ferro D, Camastra C, Cordova C, et al. Enhanced lipid peroxidation in hepatic cirrhosis. J Investig Med 1998;46:51–57.
   PubMed Web of Science ®Google Scholar
• Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 2011; 412:1297–1305.
   PubMed Web of Science ®Google Scholar
• Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59–69.
   PubMed Web of Science ®Google Scholar
• Zein CO, Lopez R, Fu X, Kirwan JP, Yerian LM, McCullough AJ, et al. Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology 2012; 56:1291–1299.
   PubMed Web of Science ®Google Scholar
• Raszeja-Wyszomirska J, Safranow K, Milkiewicz M, Milkiewicz P, Szynkowska A, Stachowska E. Lipidic last breath of life in patients with alcoholic liver disease. Prostaglandins Other Lipid Mediat. 2012;99:51–56.
   Google Scholar
• Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007; 46:1392–1403.
   PubMed Web of Science ®Google Scholar
• Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, McCullough AJ. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610–1619.
   PubMed Web of Science ®Google Scholar
• Sparvero LJ, Amoscato AA, Kochanek PM, Pitt BR, Kagan VE, Bayir H. Mass-spectrometry based oxidative lipidomics and lipid imaging: applications in traumatic brain injury. J Neurochem 2010;115:1322–1336.
   PubMed Web of Science ®Google Scholar
• Yin H, Xu L, Porter NA. Free radical lipid peroxidation: mechanisms and analysis. Chem Rev 2011;111:5944–5972.
   PubMed Web of Science ®Google Scholar
• Niki E. Lipid peroxidation: physiological levels and dual biological effects. Free Radic Biol Med 2009;47:469–484.
   PubMed Web of Science ®Google Scholar
• Capdevila J, Yadagiri P, Manna S, Falck JR. Absolute configuration of the hydroxyeicosatetraenoic acids (HETEs) formed during catalytic oxygenation of arachidonic acid by microsomal cytochrome P-450. Biochem Biophys Res Commun 1986;141:1007–1011.
   PubMed Web of Science ®Google Scholar
• Noguchi N, Yamashita H, Hamahara J, Nakamura A, Kühn H, Niki E. The specificity of lipoxygenase-catalyzed lipid peroxidation and the effects of radical-scavenging antioxidants. Biol Chem 2002;383:619–626.
   PubMed Web of Science ®Google Scholar
• Niki E. Biomarkers of lipid peroxidation in clinical material. Biochim Biophys Acta 2013. doi:pii:S0304-4165(13)00098-6. 10.1016/j.bbagen.2013.03.020.
   Google Scholar
• Feldstein AE, Lopez R, Tamimi TA, Yerian L, Chung YM, Berk M, et al. Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res 2010;51:3046–3054.
   PubMed Web of Science ®Google Scholar
• Ferro D, Basili S, Praticó D, Iuliano L, FitzGerald GA, Violi F. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood 1999;93:2945–2950.
   Google Scholar
• Vajro P, Lenta S, Pignata C, Salerno M, D’Aniello R, De Micco I, et al. Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions. Ital J Pediatr 2012;38:55.
   PubMed Web of Science ®Google Scholar
• Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675–1685.
   PubMed Web of Science ®Google Scholar
• Cheng J, Joyce A, Yates K, Aouizerat B, Sanyal AJ. Metabolomic profiling to identify predictors of response to vitamin E for non-alcoholic steatohepatitis (NASH). PLoS One 2012;7:e44106.
   PubMed Web of Science ®Google Scholar
• Pacana T, Sanyal AJ. Vitamin E and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care 2012;15: 641–648.
   PubMed Web of Science ®Google Scholar
• Pattison DI, Hawkins CL, Davies MJ. What are the plasma targets of the oxidant hypochlorous acid?A kinetic modeling approach. Chem Res Toxicol 2009;22:807–817.
   PubMed Web of Science ®Google Scholar
• Niki E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: in vitro and in vivo evidence. Free Radic Biol Med 2013. doi:pii:S0891-5849(13)00127-5.
   Google Scholar
• Belkner J, Stender H, Kühn H. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J Biol Chem 1998;273:23225–23232.
   PubMed Web of Science ®Google Scholar
• Oliveira CP, Faintuch J, Rascovski A, Furuya CK Jr, Bastos Mdo S, Matsuda M, et al. Lipid peroxidation in bariatric candidates with nonalcoholic fatty liver disease (NAFLD) – preliminary findings. Obes Surg 2005;15: 502–505.
   Google Scholar
• Davies MJ. Myeloperoxidase-derived oxidation: mechanisms of biological damage and its prevention. J Clin Biochem Nutr 2011;48:8–19.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70–83.
   PubMed Web of Science ®Google Scholar
• Arnold C, Konkel A, Fischer R, Schunck WH. Cytochrome P450-dependent metabolism of omega-6 and omega-3 long-chain polyunsaturated fatty acids. Pharmacol Rep 2010;62: 536–547.
   PubMed Web of Science ®Google Scholar
• Iuliano L. Pathways of cholesterol oxidation via non- enzymatic mechanisms. Chem Phys Lipids 2011;164: 457–468.
   PubMed Web of Science ®Google Scholar
• Pikuleva IA. Cholesterol-metabolizing cytochromes P450. Drug Metab Dispos 2006;34:513–520.
   PubMed Web of Science ®Google Scholar
• van den Berg JJ, Winterbourn CC, Kuypers FA. Hypochlorous acid-mediated modification of cholesterol and phospholipid: analysis of reaction products by gas chromatography-mass spectrometry. J Lipid Res 1993;34:2005–2012.
   PubMed Web of Science ®Google Scholar
• Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta 2000;1529:126–135.
   PubMed Web of Science ®Google Scholar
• Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 1998; 273:34316–34327.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Hyogo H, Honda A, Miyazaki T, Tokushige K, Hashimoto E, et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J Gastroenterol 2012;47:1257–1266.
   Google Scholar
• Ducheix S, Montagner A, Theodorou V, Ferrier L, Guillou H. The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease. Biochem Pharmacol 2013;86:96–105.
   Google Scholar
• Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006;65:278–290.
   PubMed Web of Science ®Google Scholar
• Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 2004;44:27–42.
   PubMed Web of Science ®Google Scholar
• Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013;58: 395–398.
   PubMed Web of Science ®Google Scholar
• Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011;35:630–637.
   PubMed Web of Science ®Google Scholar
• Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006;34:57–63.
   PubMed Web of Science ®Google Scholar
• Loguercio C, Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, et al; Real Sud Group. The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007;52: 2387–2395.
   PubMed Web of Science ®Google Scholar
• Davis NC. The Influence of diet upon the liver injury produced by carbon tetrachloride. J Med Res 1924;44: 601–614.
   Google Scholar
• Slater TF, Sträuli UD, Sawyer BC. Changes in liver nucleotide concentrations in experimental liver injury. 1. Carbon tetrachloride poisoning. Biochem J 1964;93:260–266.
   Google Scholar
• Slater TF. Necrogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation. Nature 1966;209:36–40.
   PubMed Web of Science ®Google Scholar
• Recknagel RO. Carbon tetrachloride hepatotoxicity. Pharmacol Rev 1967;19:145–208.
   PubMed Web of Science ®Google Scholar
• Slater TF. Free-radical mechanisms in tissue injury. Biochem J 1984;222:1–15.
   PubMed Web of Science ®Google Scholar
• Sipes IG, Krishna G, Gillette JR. Bioactivation of carbon tetrachloride, chloroform and bromotrichloromethane: Role of cytochrome P-450. Life Sci 1977;20:1541–1548.
   PubMed Web of Science ®Google Scholar
• Poyer JL, Floyd RA, McCay PB, Janzen EG, Davis ER. Spin-trapping of the trichloromethyl radical produced during enzymic NADPH oxidation in the presence of carbon tetrachloride or bromotrichloromethane. Biochim Biophys Acta 1978;539:402–409.
   PubMed Web of Science ®Google Scholar
• Corongiu FP, Poli G, Dianzani MU, Cheeseman KH, Slater TF. Lipid peroxidation and molecular damage to polyunsaturated fatty acids in rat liver. Recognition of two classes of hydroperoxides formed under conditions in vivo. Chem Biol Interact 1986;59:147–155.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Itoh N, Hayakawa M, Piga R, Cynshi O, Jishage K, Niki E. Lipid peroxidation induced by carbon tetrachloride and its inhibition by antioxidant as evaluated by an oxidative stress marker, HODE. Toxicol Appl Pharmacol 2005;208:87–97.
   PubMedGoogle Scholar
• Niki E. Free radical initiators as source of water- or lipid-soluble peroxyl radicals. Methods Enzymol 1990; 186:100–108.
   PubMed Web of Science ®Google Scholar
• Terao K, Niki E. Damage to biological tissues induced by radical initiator 2,2’-azobis(2-amidinopropane) dihydrochloride and its inhibition by chain-breaking antioxidants. J Free Radic Biol Med 1986;2:193–201.
   PubMedGoogle Scholar
• Niki E, Takahashi M, Tsuchiya J, Komuro E, Ito E, Terao K. Role of hydrophilic diarylamines as antioxidants in the oxidations of lipids and biological tissues. Chem Biol Interact 1988;67:81–93.
   PubMed Web of Science ®Google Scholar
• Shimasaki H, Saypil WH, Ueta N. Free radical-induced liver injury. II. Effects of intraperitoneally administered 2,2’-azobis(2-amidinopropane) dihydrochloride on the fatty acid profiles of hepatic triacylglycerol and phospholipids. Free Radic Res Commun 1991;14:247–252.
   PubMed Web of Science ®Google Scholar
• Han KH, Jeon YJ, Athukorala Y, Choi KD, Kim CJ, Cho JK, et al. A water extract of Artemisia capillaris prevents 2,2’-azobis(2-amidinopropane) dihydrochloride- induced liver damage in rats. J Med Food 2006;9:342–347.
   PubMedGoogle Scholar
• Morita M, Ishida N, Uchiyama K, Yamaguchi K, Itoh Y, Shichiri M, et al. Fatty liver induced by free radicals and lipid peroxidation. Free Radic Res 2012;46:758–765.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Hayakawa M, Cynshi O, Jishage K, Niki E. Acceleration of lipid peroxidation in alpha-tocopherol transfer protein-knockout mice following the consumption of drinking water containing a radical initiator. J Oleo Sci 2008;57:577–583.
   PubMed Web of Science ®Google Scholar
• Murphy RC, Johnson KM. Cholesterol, reactive oxygen species, and the formation of biologically active metabolites. J Biol Chem 2008;283:15521–15525.
   PubMed Web of Science ®Google Scholar
• Ariyoshi K, Adachi J, Asano M, Ueno Y, Rajendram R, Preedy VR. Effect of chronic ethanol feeding on oxysterols in rat liver. Free Radic Res 2002;36:661–666.
   PubMed Web of Science ®Google Scholar
• Ferré N, Martínez-Clemente M, López-Parra M, González-Périz A, Horrillo R, Planagumà A, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol Gastrointest Liver Physiol 2009;296:G553–G562.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Fracanzani AL, Fargion S, Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol 2011;55:920–932.
   PubMed Web of Science ®Google Scholar
• Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008;44:723–738.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Yokoe N, Takemura S, Kato H, Hotta T, Matsumura N, et al. Lipid peroxidation and lysosomal enzymes in D-galactosamine hepatitis and its protection by vitamin E. Gastroenterol Jpn 1979;14:31–39.
   PubMedGoogle Scholar
• Yoshikawa T, Furukawa Y, Murakami M, Takemura S, Kondo M. Effects of vitamin E on D-galactosamine-induced or carbon tetrachloride-induced hepatotoxicity. Digestion 1982;25:222–229.
   PubMed Web of Science ®Google Scholar
• Cheeseman KH, Davies MJ, Emery S, Maddix SP, Slater TF. Effects of alpha-tocopherol on carbon tetrachloride metabolism in rat liver microsomes. Free Radic Res Commun 1987;3:325–330.
   PubMedGoogle Scholar
• Södergren E, Cederberg J, Vessby B, Basu S. Vitamin E reduces lipid peroxidation in experimental hepatotoxicity in rats. Eur J Nutr 2001;40:10–16.
   PubMed Web of Science ®Google Scholar
• Iida C, Fujii K, Koga E, Washino Y, Kitamura Y, Ichi I, et al. Effect of alpha-tocopherol on carbon tetrachloride intoxication in the rat liver. Arch Toxicol 2009;83:477–483.
   PubMed Web of Science ®Google Scholar
• Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, et al. Antioxidants vitamin E and 1-aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009;44:1121–1131.
   PubMed Web of Science ®Google Scholar
• Chung MY, Yeung SF, Park HJ, Volek JS, Bruno RS. Dietary α- and γ-tocopherol supplementation attenuates lipopolysaccharide-induced oxidative stress and inflammatory-related responses in an obese mouse model of nonalcoholic steatohepatitis. J Nutr Biochem 2010;21:1200–1206.
   PubMed Web of Science ®Google Scholar
• Yachi R, Muto C, Ohtaka N, Aoki Y, Koike T, Igarashi O, Kiyose C. Effects of tocotrienol on tumor necrosis factor-α/d-galactosamine-induced steatohepatitis in rats. J Clin Biochem Nutr 2013;52:146–153.
   Google Scholar
• Saypil WH, Shimasaki H, Ueta N. Free radical-induced liver injury. I. Effects of dietary vitamin E deficiency on triacylglycerol level and its fatty acid profile in rat liver. Free Radic Res Commun 1991;14:315–322
   PubMed Web of Science ®Google Scholar
• Kawase T, Kato S, Lieber CS. Lipid peroxidation and antioxidant defense systems in rat liver after chronic ethanol feeding. Hepatology 1989;10:815–821.
   PubMed Web of Science ®Google Scholar
• Niki E. Tocopherylquinone and tocopherylhydroquinone. Redox Rep 2007;12:204–210.
   PubMed Web of Science ®Google Scholar
• Niki E. Assessment of antioxidant capacity in vitro and in vivo. Free Radic Biol Med 2010;49:503–515.
   PubMed Web of Science ®Google Scholar
• Itoh K, Ishii T, Wakabayashi N, Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 1999;31:319–324.
   PubMed Web of Science ®Google Scholar
• Itoh K, Mimura J, Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 2010;13:1665–1678.
   PubMed Web of Science ®Google Scholar
• Bataille AM, Manautou JE. Nrf2: a potential target for new therapeutics in liver disease. Clin Pharmacol Ther 2012;92:340–348.
   PubMed Web of Science ®Google Scholar
• Xu W, Shao L, Zhou C, Wang H, Guo J. Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. Hepatogastroenterology 2011;58:2077–2080.
   Google Scholar
• Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2010;38:2293–2301.
   PubMed Web of Science ®Google Scholar
• Gong P, Cederbaum AI. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 2006;43:144–153.
   PubMed Web of Science ®Google Scholar
• Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, et al. Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 2010; 48:357–371.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Ikeda T, Yamamoto K, Ogawa H, Kamisako T. Dysregulated expression of fatty acid oxidation enzymes and iron-regulatory genes in livers of Nrf2-null mice. J Gastroenterol Hepatol 2012;27:1711–1717.
   PubMedGoogle Scholar
• Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005;54: 987–993.
   PubMed Web of Science ®Google Scholar
• Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 2009;18:424–432.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003;38:32–38.
   PubMedGoogle Scholar
• Eguchi Y, Mizuta T, Sumida Y, Ishibashi E, Kitajima Y, Isoda H, et al. The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. J Gastroenterol 2011;46:70–78.
   Google Scholar
• Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005;42:585–591.
   Google Scholar
• Malaguarnera L, Di Rosa M, Zambito AM, Dell’Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 2006;55:1313–1320.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res 2009;39: 213–222.
   PubMed Web of Science ®Google Scholar
• Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol 2012;18:3782–3786.
   Google Scholar
• Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T, Okanoue T. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2006;36:315–321.
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007;102: 1251–1258.
   PubMed Web of Science ®Google Scholar
• Beaton MD, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Phase II clinical trial of phlebotomy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;37:720–729.
   Google Scholar
• Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15:1667–1672.
   PubMed Web of Science ®Google Scholar
• Kawanaka M, Mahmood S, Niiyama G, Izumi A, Kamei A, Ikeda H, et al. Control of oxidative stress and reduction in biochemical markers by Vitamin E treatment in patients with nonalcoholic steatohepatitis: a pilot study. Hepatol Res 2004; 29:39–41.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003;98:2485–2490.
   PubMed Web of Science ®Google Scholar
• Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659–1668.
   PubMed Web of Science ®Google Scholar
• Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549–1556.
   PubMed Web of Science ®Google Scholar
• Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000;50:722–727.
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96:2711–2717.
   Google Scholar
• Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009;50:1818–1826.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770–778.
   PubMed Web of Science ®Google Scholar
• Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, et al.; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010;52:472–479.
   PubMed Web of Science ®Google Scholar
• Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al.; FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 2011;54:1011–1019.
   PubMed Web of Science ®Google Scholar
• Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006;4:1537–1543.
   PubMed Web of Science ®Google Scholar
• Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38: 414–418.
   PubMed Web of Science ®Google Scholar
• Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R. Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci 2008;53:2246–2250.
   Google Scholar
• Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis–a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338–1345.
   PubMed Web of Science ®Google Scholar
• Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008;2:196–201.
   Google Scholar
• Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, Rinella ME. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011;10:277–286.
   PubMed Web of Science ®Google Scholar
• Khoshbaten M, Aliasgarzadeh A, Masnadi K, Tarzamani MK, Farhang S, Babaei H, et al. N-acetylcysteine improves liver function in patients with non-alcoholic Fatty liver disease. Hepat Mon 2010;10:12–16.
   PubMed Web of Science ®Google Scholar
• Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009;48:587–596.
   PubMed Web of Science ®Google Scholar
• Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001;35:568–574.
   PubMed Web of Science ®Google Scholar
• Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56–62.
   PubMed Web of Science ®Google Scholar
• Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci 2004;34:57–62.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004;99:1497–1502.
   PubMed Web of Science ®Google Scholar
• Horoz M, Bolukbas C, Bolukbas FF, Sabuncu T, Aslan M, Sarifakiogullari S, et al. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol 2005;5:35.
   PubMed Web of Science ®Google Scholar
• Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2005;100:850–855.
   PubMed Web of Science ®Google Scholar
• Machado MV, Ravasco P, Jesus L, Marques-Vidal P, Oliveira CR, Proença T, et al. Blood oxidative stress markers in non-alcoholic steatohepatitis and how it correlates with diet. Scand J Gastroenterol 2008;43:95–102.
   PubMed Web of Science ®Google Scholar
• Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413–419.
   PubMed Web of Science ®Google Scholar